DETAILED ACTION
This Office Action is in response to the Applicant’s Amendment filed 12/10/25.
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Response to Amendment
The rejection of Claim 13 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention as set forth in the Non-Final Rejection filed 09/12/25 is overcome by the Applicant’s amendments.
The rejection of Claim 2 under 35 U.S.C. 102(a)(1) as being anticipated by Cao et al. (CN 109912610 A) as set forth in the Non-Final Rejection filed 09/12/25 is overcome by the cancellation of the claim.
The rejection of Claims 1, 4, 6-9, 12, and 13 under 35 U.S.C. 102(a)(1) as being anticipated by Cao et al. (CN 109912610 A) as set forth in the Non-Final Rejection filed 09/12/25 is overcome by the Applicant’s amendments.
The rejection of Claims 2 and 3 under 35 U.S.C. 103 as being unpatentable over Wolleb et al. (WO 2018/043761 A1) as set forth in the Non-Final Rejection filed 09/12/25 is overcome by the cancellation of the claims.
The rejection of Claims 1, 4, 5, 7-10, 12, and 13 under 35 U.S.C. 103 as being unpatentable over Wolleb et al. (WO 2018/043761 A1) as set forth in the Non-Final Rejection filed 09/12/25 is overcome by the Applicant’s amendments.
Claim Objections
Claims 1 and 4-13 are objected to because of the following informalities:
Claim 1, which the other claims are dependent upon, recites the following limitation:
PNG
media_image1.png
54
626
media_image1.png
Greyscale
(page 2), which is an unnecessary limitation as due to the newly added amendments to Claim 1 as one of Y1-7 must always be N and Y6-7 can only be N, C-H, or C-D. Hence, the above limitation should be deleted.
Appropriate correction is required.
Allowable Subject Matter
Claims 1 and 4-13 are currently objected to due to minor informalities as set forth above, but would be allowable if rewritten to overcome the objection.
Examiner’s Note: The Office has relied on national phase publication US 2019/0248804 A1 as the English equivalent of WIPO publication WO 2018/043761 A1 (herein referred to as “Wolleb et al.”). Unless otherwise noted, all figure, page, and paragraph numbers refer to numbers found in the national phase publication.
The closest prior art is provided by Wolleb et al. (WO 2018/043761 A1), which discloses compounds of the following form:
PNG
media_image2.png
148
394
media_image2.png
Greyscale
([0028]) where Y = S or O, one of X1-8 = N, and at least two of X9-11 = N; an embodiment is disclosed:
PNG
media_image3.png
362
314
media_image3.png
Greyscale
(page 51). However, it is the position of the Office that neither Wolleb et al. singly nor in further combination with any other prior art discloses any of the specific compounds as recited in the claim, particularly in regards to the nature (and position) of the substituent groups attached to the core aza-dibenzofuran.
Response to Arguments
Applicant’s arguments on pages 97-103 with respect to the deficiencies of the previously cited prior art in view of the new amendments to the scope of Chemical Formula 1 as recited in Claim 1 have been fully considered and are persuasive. Hence, the rejections have been withdrawn.
Conclusion
11. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAY L YANG whose telephone number is (571)270-1137. The examiner can normally be reached Mon-Fri, 6am-3pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer A Boyd can be reached at 571-272-7783. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JAY YANG/Primary Examiner, Art Unit 1786